862
Ewin, J.H. and Horrobin, D.F. Fine wines and fish oil: the life of Hugh MacDonald Sinclair
Oxford University Press, 362pp 2001. (Abstract)
863
Horrobin, D.F. The paradox of antioxidants and cancer [letter]
Am J Clin Pract 2001; 74(4): 555-6. (Full text)
864
Horrobin, D.F. The madness of Adam and Eve. How schizophrenia shaped humanity.
Bantam, London. 275 pp 2001. (Abstract)
865
Horrobin, D.F. More on burns after photodynamic therapy. Might doctors performing the study have been given the wrong injection instructions? [letter]
Br Med J 2001; 322(7279): 171-2. (Full text)
866
Horrobin, D.F. New drug discovery techniques are not so revolutionary [letter]
Br Med J 2001; 322(7280): 239. (Full text)
867
Horrobin, D.F. Burns After Photodynamic Therapy [letter]
Br Med J eletters: http://bmj.com/cgi/eletters/322/7279/171/a#12498 2001. (Full text)
868
Horrobin, D.F. Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase
Hum Psychopharmacol 2001; 16(1): 45-52. (Abstract)
869
Horrobin, D.F. Disorders of phospholipid metabolism in schizophrenia, affective disorders and neurodegenerative disorders
In: Fatty Acids: Physiological and Behavioural Functions. Mostofsky, D.I., Yehuda, S. and Salem, N. (Eds.), Humana Press, Totawa, NJ 2001: 331-4.
870
Horrobin, D.F. Gamma-linolenic acid in diabetes
In: Huang, Y.S.; Ziboh, V.A. (Eds.) Gamma-linolenic acid: recent advances in biotechnology and clinical applications. American Oil Chemists Society, Champaign, Illinois. 2001: 105-11. (Abstract)
871
Horrobin, D.F. [Foreward]
In: Yabrov, A.A.; Slonim, M.A. How man exists. 1stBooks Library, Indiana. 2001: V.
872
Horrobin, D.F. Realism in drug discovery - could Cassandra be right?
Nature Biotechnol 2001; 19(12): 1099-100.
873
Horrobin, D.F. Something rotten at the core of science?
Trends Pharmacol Sci 2001; 22(2): 51-2. (Full text)(Abstract)
874
Horrobin, D.F.; Bennett, C.N.; Peet, M. Correlation between clinical improvement and red cell fatty acid changes when treating schizophrenia with eicosapentaenoic acid
Schizophr Res 2001; 49: 232.
875
Horrobin, D.F. and Peet, M. Ethyl-eicosapentaenoate (LAX-101) in treatment-unresponsive depression (Abstract)
Bipolar Disorders 2001; 3: 42.
876
Horrobin, D.F. and Peet, M.A. A dose-ranging study of ethyl-eicosapentaenoate in treatment-unresponsive depression (Abstract)
Biol Psychiatry 2001; 49: 37S.
877
Peet, M. and Horrobin, D.F. The role of phospholipids in schizophrenia (Abstract)
Presented at: Society of Biological Psychiatry Annual Meeting 2001.
878
Puri, B.K.; Bydder, G.M.; Chaudhuri, K.R.; Al Saffar, B.Y.; Curati, W.L.; White, S.J.; Mitchell, L.; Hajnal, J.V.; Horrobin, D.F. MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine
Neuroreport 2001; 12(9): 1821-4. (Abstract)
879
Puri, B.K.; Counsell, S.J.; Hamilton, G.; Richardson, A.J.; Horrobin, D.F. Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover
Int J Clin Pract 2001; 55(8): 560-3. (Abstract)
880
Puri, B.K. and Horrobin, D.F. Decrease in cerebral ventricular volume in end-stage Huntington's disease treated with puri.ed eicosapentaenoic acid (Poster)
Presented at: International Society for Magnetic Resonance in Medicine Meeting, Glasgow, UK, April 2001.